Journal article
Atypical chronic myeloid leukemia: a rare entity with management challenges
Future oncology (London, England), Vol.14(2), pp.177-185
01/01/2018
DOI: 10.2217/fon-2017-0334
PMID: 29226717
Abstract
The aim of our study was to review the clinicopathologic features and management of atypical chronic myeloid leukemia (aCML). Relevant manuscripts published in English were searched using PubMed. aCML is diagnosed as per WHO 2016 classification in the presence of leukocytosis >= 13 x 109/l with circulating neutrophil precursors >= 10%, monocytes less than 10%, minimal basophils, hypercellular bone marrow with granulocytic proliferation and dysplasia, bone marrow blast less than 20% and absence of BCR/ABL fusion gene. Common cytogenetic features and mutations include trisomy 8, and mutations in SETBP1 and ETNK1. Median survival is 1-2 years. Hematopoietic stem cell transplant may be the only curative option. Ruxolitinib and dasatinib are emerging therapeutic options. Thus, aCML is a rare entity with poor survival. Novel therapies are needed.
Details
- Title: Subtitle
- Atypical chronic myeloid leukemia: a rare entity with management challenges
- Creators
- Prajwal Dhakal - Michigan State UniversityKrishna Gundabolu - University of Nebraska Medical CenterCatalina Amador - University of Nebraska Medical CenterSupratik Rayamajhi - Michigan State UniversityVijaya Raj Bhatt - University of Nebraska Medical Center
- Resource Type
- Journal article
- Publication Details
- Future oncology (London, England), Vol.14(2), pp.177-185
- Publisher
- Future Medicine Ltd
- DOI
- 10.2217/fon-2017-0334
- PMID
- 29226717
- ISSN
- 1479-6694
- eISSN
- 1744-8301
- Number of pages
- 9
- Grant note
- University of Nebraska Medical Center, College of Medicine, Physician-Scientist Training Program
- Language
- English
- Date published
- 01/01/2018
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359670102771
Metrics
23 Record Views